Treatment rechallenge after trastuzumab-deruxtecan–related interstitial lung disease: A multi-institution cohort study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Trastuzumab and T-DXd are effective in HER2-positive gastric and GEJ cancers, moving towards earlier intervention stages. A meta-analysis of T-DXd showed significant efficacy and manageable safety in ...
Trastuzumab deruxtecan-THP was associated with a statistically significant and clinically meaningful improvement in pathologic complete response rate vs standard of care. The DESTINY-Breast11 trial ...
Trastuzumab deruxtecan has shown efficacy in patients with previously treated human epidermal growth factor receptor 2 (HER2)–positive advanced or metastatic breast cancer. The efficacy and safety of ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved trastuzumab-strf as a biosimilar to trastuzumab for the treatment of certain patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results